
Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, revealed positive safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.
The trial evaluated the proprietary combination of Clearmind's proprietary psychedelic molecule MEAI and SciSparc's CannAmide for treating alcohol consumption.